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ABSTRACT
Objectives Mavrilimumab, a human monoclonal
antibody targeting the alpha subunit of the granulocyte-
macrophage colony-stimulating factor receptor, was
evaluated in a phase 2 randomised, double-blind,
placebo-controlled study to investigate efﬁcacy and safety
in subjects with rheumatoid arthritis (RA).
Methods Subcutaneous mavrilimumab (10 mg, 30 mg,
50 mg, or 100 mg) or placebo was administered every
other week for 12 weeks in subjects on stable
background methotrexate therapy. The primary endpoint
was the proportion of subjects achieving a ≥1.2
decrease from baseline in Disease Activity Score
(DAS28-CRP) at week 12.
Results 55.7% of mavrilimumab-treated subjects met
the primary endpoint versus 34.7% placebo (p=0.003) at
week 12; for the 10 mg, 30 mg, 50 mg, and 100 mg
groups, responses were 41.0% (p=0.543), 61.0%
(p=0.011), 53.8% (p=0.071), and 66.7% (p=0.001)
respectively. Response rate differences from placebo
were observed at week 2 and increased throughout the
treatment period. The 100 mg dose demonstrated a
signiﬁcant effect versus placebo on DAS28-CRP<2.6
(23.1% vs 6.7%, p=0.016), all categories of the
American College of Rheumatology (ACR) criteria
(ACR20: 69.2% vs 40.0%, p=0.005; ACR50: 30.8% vs
12.0%, p=0.021; ACR70: 17.9% vs 4.0%, p=0.030),
and the Health Assessment Questionnaire Disability Index
(−0.48 vs −0.25, p=0.005). A biomarker-based disease
activity score showed a dose-dependent decrease at
week 12, indicating suppression of disease-related
biological pathways. Adverse events were generally mild
or moderate in intensity. No signiﬁcant hypersensitivity
reactions, serious or opportunistic infections, or changes
in pulmonary parameters were observed.
Conclusions Mavrilimumab induced rapid clinically
signiﬁcant responses in RA subjects, suggesting that
inhibiting the mononuclear phagocyte pathway may
provide a novel therapeutic approach for RA.
The Corresponding Author has the right to grant on
behalf of all authors and does grant on behalf of all
authors, an exclusive licence (or non exclusive for
government employees) on a worldwide basis to the
BMJ Publishing Group Ltd to permit this article (if
accepted) to be published in ARD and any other
BMJPGL products and sublicences such use and
exploit all subsidiary rights, as set out in our license.
INTRODUCTION
Despite the many treatments introduced for
rheumatoid arthritis (RA), signiﬁcant proportions
of patients fail to achieve meaningful responses and
are not adequately controlled.1 New therapies with
novel mechanisms of action are still needed to
address this unmet need. We postulate that
direct modulation of macrophage function via
granulocyte-macrophage colony-stimulating factor
receptor (GM-CSFR) inhibition may provide a treat-
ment option in RA. GM-CSF may play a central
role in the pathogenesis of RA through the activa-
tion, differentiation and survival of neutrophils and
macrophages.2 Macrophages promote synovitis via
release of cytokines, chemokines, reactive oxygen
and nitrogen intermediates, proteases and micropar-
ticles. The number of macrophages in synovial
tissue is correlated with radiographic progression;3
reductions in CD68+ macrophages correlate with
improvement in disease activity scores.4–6 RA
patients exhibit increased GM-CSF levels in syn-
ovial ﬂuid, plasma and synoviocytes,7–9 and recom-
binant GM-CSF has been reported to exacerbate
disease in those patients.10–12
Mavrilimumab (CAM-3001) is a fully-human
monoclonal antibody targeting the alpha subunit
of GM-CSFR. In a phase 1 single ascending intra-
venous dose study in 32 subjects with RA, mavrili-
mumab showed a safety and tolerability proﬁle
supporting clinical development, and biological
activity on acute phase reactants.13 This phase 2a
study evaluated the efﬁcacy and safety of sub-
cutaneous (SC) mavrilimumab in subjects with
moderate-to-severe active RA. This is the ﬁrst study
to investigate macrophage inhibition through direct
blockage of GM-CSFRα as a novel therapeutic
approach in RA.
METHODS
Study design
This multicentre, randomised, double-blind,
placebo-controlled study (EARTH Study;
NCT01050998) evaluated the efﬁcacy, safety and
tolerability proﬁle of ascending SC mavrilimumab
doses in combination with stable methotrexate
in subjects with moderate-to-severe active RA.
Subjects were randomised between February 2010
▸ http://dx.doi.org/10.1136/
annrheumdis-2012-202275
▸ http://dx.doi.org/10.1136/
annrheumdis-2012-202775
▸ http://dx.doi.org/10.1136/
annrheumdis-2012-202864
▸ http://dx.doi.org/10.1136/
annrheumdis-2013-203261
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and March 2011 at 53 centres across 10 Eastern European
countries.
Subjects were randomised using an interactive voice response
system in a 2:1 ratio (active:placebo) within each cohort and
received, either 10, 30, 50, or 100 mg SC doses of mavrilimu-
mab or placebo every other week for 12 weeks, followed by a
12-week follow-up period.
Doses and administration frequency were based on phase 1
data13 and pharmacokinetic-pharmacodynamic modelling.14 For
Cohorts 1–3, dose escalation to the next cohort was based on a
cumulative safety data review after ≥18 subjects completed day
29 dosing; for Cohort 4, six subjects received mavrilimumab
100 mg for the entire treatment period (12 weeks) and based
on the safety review, randomisation was resumed.
Background stable non-steroidal anti-inﬂammatory drugs and
oral corticosteroids (≤10 mg/day prednisolone or equivalent)
were allowed.
The study was conducted in accordance with the principles
of the Declaration of Helsinki and the International Conference
on Harmonisation Guidance for Good Clinical Practice.
Independent ethics committee approval was obtained. All sub-
jects provided written informed consent. The protocol was
jointly developed by the academic authors and the sponsor,
MedImmune, who collected the data. Authors had full access
to data and certify the veracity and completeness of the data
and the data analysis.
Subjects
Subjects were 18−80 years with at least moderately active
(Disease Activity Score (DAS)28-CRP ≥3.2)15 adult-onset RA of
≥3 months duration,16 despite methotrexate (7.5–25 mg/week)
treatment for ≥12 weeks, and positive for anti-cyclic citrullinated
peptide antibody (ACPA, >5 IU/ml; Axis Shield by ELISA) and/or
rheumatoid factor (>14 IU/ml; Tina-Quant, Roche Diagnostics,
Indianapolis, Indiana, USA and ELISA, Immco Diagnostics,
Buffalo, New York, USA). All subjects received stable methotrex-
ate (for ≥4 weeks) with supplemental folic acid ≥5 mg/week.
Subjects previously treated with 1 biologic therapy for RA but dis-
continued for lack of efﬁcacy were eligible for entry in the study.
Subjects with symptomatic or uncontrolled lung disease, active
infection, or at a high risk of infection were excluded.
Efﬁcacy assessments
Efﬁcacy assessments were performed at baseline and every
2 weeks during the 12-week treatment period and at 2 weeks,
1 month, and 3 months after the last dose. The primary end-
point was deﬁned as the proportion of subjects achieving a
reduction of ≥1.2 points from baseline in DAS28-CRP17 at
week 12.
Secondary endpoints included time to onset of response and
DAS28-CRP<2.6, improvements to the Health Assessment
Questionnaire Disability Index (HAQ-DI)18 score, European
League Against Rheumatism (EULAR), and American College
of Rheumatology (ACR) response criteria.
Biomarker assessment
Twelve biomarkers (c-reactive protein (CRP), epidermal growth
factor (EGF), Leptin, IL-6, MMP-1, MMP-3, Resistin, SAA,
TNFR-I, VCAM-1, VEGF-A, YKL-40) were measured in serum
samples from baseline and day 88 (Meso Scale Discovery
MULTI-ARRAY platform). A multi-biomarker disease activity
(MBDA) score was calculated for each sample by combining
the concentrations of these biomarkers in the Vectra DA
algorithm. The algorithm was trained and validated in previous
studies using DAS28-CRP as a reference measure.19–21
Safety and tolerability assessments
Respiratory monitoring (chest x-ray, forced expiratory volume
(FEV1), forced vital capacity (FVC), diffusing capacity of the
lung for carbon monoxide (DLCO), and dyspnoea score) was
performed at baseline and throughout the study because
GM-CSF inhibition could affect alveolar macrophage function
and surfactant homeostasis in the lung.22 23 The protocol man-
dated treatment discontinuation if pulmonary function deterio-
rated by >20% of baseline spirometry or DLCO values and for
the changes to be reported as adverse events (AEs).
Serum surfactant D (SP-D) and KL-6 levels (ELISA; Sanko
Junyaku Co, Japan)—established biomarkers for lung
damage24–27—were measured at baseline and on days 29, 85,
and 169. Other safety assessments included the incidence of
AEs and serious AEs (SAEs) and routine laboratory testing.
Pharmacokinetics and immunogenicity
Serum mavrilimumab concentrations were measured from blood
samples collected at the ﬁrst and last doses, and at pre-designated
timepoints using a validated electrochemiluminescence assay.
The presence of anti-drug antibodies (ADA) was determined
using a two-step approach: an electrochemiluminescence screen-
ing immunoassay and a conﬁrmatory inhibition assay.
Statistical methods
Sample size calculations were based on the primary endpoint
at week 12. We assumed a placebo response rate of 10%, a 15%
drop-out rate, and used a two-sided signiﬁcance level of 0.05,
and a 2:1 (active:placebo) randomisation ratio. The total
sample size of 216 subjects provided 86% power to detect a
20% difference in response rate between the combined mavrili-
mumab arms and placebo using Fisher ’s exact test. All response
rates, including the primary endpoint, ACR20, ACR50, and
ACR70, were analysed using Fisher ’s exact test. Changes from
baseline in DAS28-CRP and HAQ-DI were analysed using a
mixed-model repeated measures analysis with a covariate for
baseline DAS28-CRP. The time-to-onset of response was ana-
lysed using a log-rank test.
All efﬁcacy analyses were conducted on the intent-to-treat
(ITT) population (all subjects randomised, regardless of
whether they received treatment). Each analysis was conducted
to compare the combined placebo and combined mavrilimumab
groups, followed by comparison of the combined placebo group
with each of the mavrilimumab dose cohorts. Analysis of
safety data was carried out on the safety population (all sub-
jects who received any dose of study medication).
For the primary endpoint as well as the other responder ana-
lyses, a non-responder imputation was used for subjects who
withdrew from study treatment, changed the dose of background
methotrexate, or received other RA medication. Other missing
data points were imputed using last-observation-carried-forward
methodology. No imputation was applied for the DAS28-CRP
change from baseline analysis. Noncompartmental analysis was
performed on individual pharmacokinetic (PK) data for the ﬁrst
and last doses. Biomarker data were analysed by Mann-Whitney
U test and linear regression. Signiﬁcance for individual biomarkers
was evaluated by false discovery rate.28
RESULTS
Of 427 subjects screened, 239 were subsequently randomised
into the four cohorts. Of these, 233 were included in the ITT
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population, 216 completed the study, and 17 discontinued, three
of which were due to AEs (ﬁgure 1). The treatment groups were
generally balanced in terms of baseline and disease characteris-
tics (table 1); the 50 mg group had a slightly higher proportion
of female subjects and a lower mean dose of methotrexate.
Efﬁcacy
Administration of mavrilimumab (all doses combined, n=158)
was associated with a signiﬁcantly higher proportion of
subjects achieving a ≥1.2-point reduction in DAS28-CRP
than placebo (n=75) at week 12 (55.7% vs 34.7%; p=0.003)
(ﬁgure 2A). A signiﬁcant difference in DAS28-CRP adjusted
mean change from baseline compared with placebo was seen
for the 50 mg (−0.38, 95% CI −0.67 to −0.08; p=0.013) and
100 mg (−0.44, 95% CI −0.74 to −0.14; p=0.004) cohorts as
early as week 2 (ﬁgure 2B). DAS28-CRP<2.6 rates increased
over time in all treated groups; the 100 mg dose demonstrated a
signiﬁcant effect (23.1% vs 6.7%; p=0.016) by week 12 and
the number of subjects achieving DAS28-CRP<2.6 was still
increasing at week 12 (ﬁgure 2A–C).
At the 100 mg dose, signiﬁcant improvement in HAQ-DI
versus placebo was observed from week 6 (−0.36 vs −0.19;
p=0.041) through week 12 (−0.48 vs −0.25; p=0.005; ﬁgure
2D), with 74.4% mavrilimumab vs 48.0% placebo subjects
reporting clinically signiﬁcant improvements (≥0.25; p=0.009).
The adjusted mean differences (95% CI) from baseline versus
placebo were −0.17 (−0.33, −0.01) and −0.23 (−0.39, −0.07).
The largest treatment effect, as assessed by ACR criteria, was
seen in the 100 mg dose at week 12 vs placebo (ACR20 69.2 vs
40.0%, p=0.005; ACR50 30.8 vs 12.0%, p=0.021; ACR70
17.9 vs 4.0%, p=0.030) (ﬁgure 3A) with a signiﬁcant separation
from placebo seen as early as week 4 (ACR20 53.8% vs 20.0%
p<0.001) (ﬁgure 3B–D). A larger proportion of subjects receiv-
ing mavrilimumab showed a moderate or good EULAR
response versus placebo (67.7 vs 50.7%; p=0.025). The highest
proportion of moderate (46.2%) or good responders (30.8%)
was seen in the 100 mg group.
Signiﬁcant changes were seen from week 2 in CRP
(p=0.004) and erythrocyte sedimentation rate (ESR) (p=0.005)
in the mavrilimumab groups versus placebo, and in swollen
and tender joint count from week 4 (p=0.002 and p=0.011,
respectively) (see web only ﬁles).
Efﬁcacy observed in the 100 mg group at week 12 was main-
tained through the follow-up to week 24, manifested both as a
≥1.2-point reduction in DAS28-CRP (59.0% vs 33.3% placebo;
p=0.010) and ACR20 response (56.4% vs 30.7% placebo;
p=0.009). This ‘post-treatment’ maintenance of response
was not observed for DAS28-CRP<2.6, ACR50, and ACR70
(ﬁgures 2C and 3C,D).
Ninety-one per cent of subjects in the ITT population had
sufﬁcient sample available for biomarker analyses (placebo
(n=65); mavrilimumab (n=146): 10 mg (n=35), 30 mg (n=37),
50 mg (n=38), and 100 mg (n=36)). At baseline, MBDA scores
reﬂected the severe disease activity measured by DAS28-CRP.
The MBDA score decreased more in the combined
mavrilimumab-treated subjects versus placebo at week 12
(p=0.008) and decreases were dose-dependent (p<0.001)
(ﬁgure 2E). There were also dose-dependent decreases in the
constituent biomarkers CRP, IL-6, MMP-3, SAA, and YKL-40
(false discovery rate <0.05) (see web only ﬁles). Signiﬁcant
reductions in markers of systemic inﬂammation (CRP, SAA,
IL-6) were observed within 1 month, with signiﬁcant changes
in YKL40 and MMP3 not being observed until week 12.
Safety and tolerability
Over the 24-week study period, 36 (45.6%) subjects receiving
placebo and 91 (56.9%) receiving mavrilimumab experienced an
AE (table 2).
Figure 1 Patient disposition (ITT population).
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Within the 12-week treatment period, 26 (32.9%) subjects
receiving placebo and 73 (45.6%) subjects receiving mavrilimu-
mab experienced an AE.
The protocol mandated that reductions in DLCO >20% of
baseline be reported as AEs regardless of clinical signiﬁcance. As
such, these were the most frequently reported AEs (5 (6.3%)
placebo and 19 (11.9%) mavrilimumab). Only two subjects
(one placebo and one in the 10 mg cohort) discontinued
because of DLCO reductions; no lung toxicities were detected
as assessed by an independent pulmonologist. In the 30, 50,
and 100 mg groups, there was no difference in DLCO event
rate compared with placebo. Further, no clinically signiﬁcant
changes in serum SP-D and KL-6 were observed over the
3 months of treatment or 3 months follow-up across treatment
groups (see web only ﬁles).
There were no clinically signiﬁcant or persistent changes in
lung function tests performed by spirometry. Nasopharyngitis
and upper respiratory tract infections (all mild-to-moderate in
severity) were the next most common events. Most AEs were
mild or moderate in intensity.
There were no deaths during the study, and the frequency or
severity of AEs was not dependent on mavrilimumab dose.
SAEs were reported in one subject receiving placebo (worsening
of RA, which resulted in discontinuation) and four subjects
receiving mavrilimumab; two in the 10 mg cohort, (intervertebral
disc disorder and spontaneous abortion); and two in the 30 mg
cohort, (fracture of the humerus and fracture of the patella).
None of the SAEs was considered related to the study drug.
No instances of severe hypersensitivity, anaphylaxis, or
serious injection site reactions (local or systemic) were reported
during the treatment period. One (2.5%) subject in the 50 mg
cohort experienced a mild rash, which was assessed as a hyper-
sensitivity reaction that resolved spontaneously within 10 h.
Pharmacokinetics and Immunogenicity
Maximum serum concentration of mavrilimumab was observed
approximately 3 days postdose, and PK steady-state was
reached by day 57 in all dose groups. The PK exposure was
more than dose-proportional. At the 100 mg dose, the terminal-
phase PK half-life was ∼13 days.
During the study, 23 subjects developed detectable ADA
(3 placebo and 20 treated). Generally, ADA titres were low and
transient and did not impact the PK. High-titre ADAs were
reported in 1 placebo (1.3%) subject and 10 mavrilimumab
(6.3%; 3 at 10 mg, 4 at 30 mg, 1 at 50 mg, and 2 at 100 mg)
subjects. Although the presence of ADA in these subjects was
associated with reduced PK exposure, no correlation was
observed with tolerability or tachyphylaxis.
DISCUSSION
New therapeutic options capable of delivering a profound and
rapid onset of action are desirable in RA because of the chronic
Table 1 Baseline and disease characteristics (Intent-to-treat population)
Placebo (n=75)
Mavrilimumab
10 mg (n=39) 30 mg (n=41) 50 mg (n=39) 100 mg (n=39) Total (n=158)
Demography
Age, mean (SD) 50.9 (12.7) 52.2 (12.2) 49.7 (11.9) 53.3 (10.2) 49.3 (11.7) 51.1 (11.6)
Gender, n (%)
Male 9 (12.0) 7 (17.9) 5 (12.2) 2 (5.1) 5 (12.8) 19 (12.0)
Female 66 (88.0) 32 (82.1) 36 (87.8) 37 (94.9) 34 (87.2) 139 (88.0)
Race, n (%)
White 75 (100.0) 39 (100.0) 38 (92.7) 39 (100.0) 39 (100.0) 155 (98.1)
Other 0 (0) 0 (0) 3 (7.3) 0 (0) 0 (0) 3 (1.9)
Weight (kg), mean (SD) 69.7 (13.9) 68.5 (15.2) 72.8 (14.5) 67.7 (13.2) 71.9 (10.6) 70.2 (13.5)
BMI (kg/m2), mean (SD) 26.1 (5.4) 25.1 (4.9) 26.6 (5.7) 26.1 (4.7) 26.9 (4.2) 26.2 (4.9)
Baseline characteristics
Disease duration (years), mean (SD) 7.5 (7.7) 9.8 (6.9) 5.6 (5.5) 7.5 (7.4) 6.4 (7.1) 7.3 (6.9)
Methotrexate dose, n (%)
Low (<12.5 mg/week) 23 (30.7) 11 (28.2) 16 (39.0) 20 (51.3) 14 (35.9) 61 (38.6)
Medium (≥12.5–<20 mg/week) 43 (57.3) 23 (59.0) 21 (51.2) 15 (38.5) 24 (61.5) 83 (52.5)
High (≥20 mg/week) 9 (12.0) 5 (12.8) 4 (9.8) 4 (10.3) 1 (2.6) 14 (8.9)
Concomitant steroids, n (%) 37 (49.3) 20 (51.3) 17 (41.5) 16 (41.0) 19 (48.7) 72 (46.0)
Prior biologic therapy 4 (5.3) 7 (17.9) 1 (2.4) 0 (0.0) 0 (0.0) 8 (5.1)
RF positive, n (%) 65 (86.7) 39 (100.0) 39 (95.1) 36 (92.3) 34 (87.2) 148 (93.7)
ACPA positive, n (%) 65 (86.7) 32 (82.1) 38 (92.7) 35 (89.7) 33 (84.6) 138 (87.3)
Baseline disease activity
DAS28-CRP, mean (SD) 5.6 (1.0) 5.3 (1.0) 5.5 (1.0) 5.3 (1.0) 5.4 (0.7) 5.4 (0.9)
Swollen joint count, mean (SD) 14.7 (8.6) 15.1 (10.6) 13.8 (8.7) 13.3 (10.1) 12.6 (6.1) 13.7 (9.0)
Tender joint count, mean (SD) 24.0 (12.5) 21.1 (12.9) 23.9 (12.1) 25.9 (12.3) 21.5 (10.2) 23.1 (11.9)
Patient pain (mm), mean (SD) 61.8 (19.8) 57.5 (23.8) 58.6 (24.1) 58.1 (18.7) 57.7 (15.8) 58.0 (20.8)
Patient global assessment of disease activity (mm), mean (SD) 61.9 (19.4) 58.0 (21.9) 60.5 (21.1) 59.7 (17.4) 58.1 (14.2) 59.1 (18.8)
Physician global assessment of disease activity (cm), mean (SD) 6.3 (1.3) 5.2 (1.9) 6.1 (1.6) 6.3 (1.6) 5.7 (1.4) 5.8 (1.7)
HAQ-DI, mean (SD) 1.5 (0.6) 1.4 (0.6) 1.4 (0.6) 1.5 (0.6) 1.5 (0.5) 1.4 (0.6)
CRP (mg/l), geometric mean (CV%) 5.8 (165.9) 4.3 (119.9) 5.9 (136.4) 5.1 (174.6) 6.1 (121.5) 5.3 (145.7)
ESR (mm/hr), geometric mean (CV%) 33.4 (58.3) 31.1 (54.1) 39.6 (55.7) 39.6 (49.9) 31.9 (50.8) 35.3 (53.5)
ACPA, anti-citrullinated protein antibody; BMI, body mass index; CRP, c-reactive protein; CV, coefficient of variation; DAS, disease activity score; ESR, erythrocyte sedimentation
rate; HAQ-DI, Health Assessments Questionnaire-Disability Index; RF, rheumatoid factor; SD, standard deviation.
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progressive nature of the disease. Despite a variety of effective
therapies currently available for the treatment of RA, many
patients still fail to achieve clinical remission, show an inad-
equate response, or cannot maintain a response.1 29–31
Our study shows that mavrilimumab, the ﬁrst investiga-
tional human monoclonal antibody to target GM-CSFRα,
improves the signs and symptoms of RA in subjects with
active disease despite stable methotrexate treatment. The
study met its primary endpoint, and rapid and sustained
improvement was demonstrated by DAS28-CRP, HAQ-DI, and
ACR responses, particularly at the 100 mg dose. Signiﬁcant
improvements in DAS28-CRP were seen as early as week 2 at
the two highest doses (50 and 100 mg), and in all dose groups,
scores continued to improve throughout the 12-week treatment
period. After treatment was discontinued at week 12, responses
were sustained for ≥4 weeks; these diminished over the
12-week off-treatment period, but DAS28-CRP and ACR20
responses were maintained in the 100 mg group throughout
this follow-up period. At week 24, the treatment response was
maintained for HAQ-DI, swollen and tender joint counts, but
there was no difference from placebo for the physician and
patient global assessments, patient pain, CRP, and ESR. Of
note is the observed placebo response rate, which was higher
than assumed in the sample size calculation. Despite this, the
primary endpoint was met and signiﬁcant improvements were
observed. Moreover, the differences in baseline characteristics in
the 50 mg group were not found to account for the lower pro-
portion of subjects achieving a ≥1.2-point reduction in
DAS28-CRP or ACR20 in that treatment group.
Improvements in the MBDA composite scores complement
and support the dose-dependent decrease in disease activity
over the 12 weeks of treatment. Suppression of individual
Figure 2 (A−E) Efﬁcacy according to DAS-28 and Health Assessment Questionnaire Disability Index (HAQ-DI) assessments (ITT population).
(A) DAS28-CRP responses by treatment group at week 12. (B) Mean DAS28-CRP by visit. (C) Time to onset of DAS28-CRP<2.6. (D) Adjusted mean
HAQ-DI change from baseline by visit. (E) Changes in MBDA Score from baseline seen at week 12.
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biomarkers within the panel suggests a beneﬁcial modulation
of pathophysiological pathways associated with RA including
global inﬂammation (CRP, IL-6, SAA) and intra-articular path-
ology (MMP3, YKL-40).32–36 Changes in acute phase proteins
and IL-6 occurred within 1 month, suggesting a direct effect on
IL-6 production and consequently acute phase reactants.
Chronic suppression of IL-6 with mavrilimumab may result in
some of the beneﬁcial mechanisms ascribed to IL-6 therapy in
RA, such as suppressing Th17 cells, either indirectly37 or dir-
ectly.38–40 The direct effects of GM-CSF inhibition on MMP3
and YKL-40 has not, to our knowledge, been described previ-
ously, but may indicate a beneﬁcial effect on cartilage degrad-
ation. Further research is required to understand the effect of
mavrilimumab on MMP3 biology in circulation and the joint.
Although we only evaluated the effects of mavrilimumab over
12 weeks, it was particularly encouraging that at the highest
(100 mg) dose, 23.1% of subjects achieved DAS28-CRP<2.6
(placebo: 6.7%), and 17.9% showed an ACR70 response (placebo:
4.0%). Separation between the placebo and active groups was
observed as early as week 4 for DAS28-CRP<2.6, suggesting a
rapid onset of action even for this high-hurdle endpoint. The
number of subjects achieving DAS28-CRP<2.6 and/or ACR70
response was still rising at 12 weeks, suggesting that peak efﬁcacy
may not have been achieved. It has been shown previously that
response to some biologic treatments continues to increase over
the ﬁrst 24 weeks of treatment, and a signiﬁcant proportion of
partial responders and non-responders at week 12 may go on to
achieve a clinical response with continued treatment.41
The safety proﬁle was consistent with a previous phase 1
study of mavrilimumab in subjects with RA.13 Due to the link
between GM-CSF and alveolar macrophage function and clear-
ance of lung surfactant proteins, we carried out intensive
pulmonary lung function tests as well as assays for biomarkers
of lung damage such as SP-D and KL-6. At the study start,
there was considerable variability in DLCO measurements, con-
tributing to the increase in reported AEs in the 10 mg group.
With greater experience with DLCO measurements, this AE
rate was not observed in the subsequent cohorts. No meaning-
ful differences were noted for SP-D and KL-6 between the
active and placebo groups. Further, SP-D and KL-6 levels at
baseline were representative of those described for healthy con-
trols and RA patients with no interstitial lung disease.42–44 No
serious or opportunistic infections or severe hypersensitivity
reactions were reported in this patient population during the
observation period.
The PK of mavrilimumab14 was nonlinear with dose due to
GM-CSFR-mediated clearance. One placebo (1.3%) and 10
mavrilimumab-treated subjects (6.3%) developed ADA with a
titre ≥4. Most incidences of ADA occurred in the lower dose
groups (10 and 30 mg). Although these instances were asso-
ciated with somewhat reduced PK exposure; there was no
apparent correlation between ADA and hypersensitivities or
reduced clinical responses. Longer-term studies will be neces-
sary to understand the potential for mavrilimumab ADAs to
affect the safety and/or efﬁcacy proﬁle of the molecule.
There are some important limitations to our study. It was a
short-term, early phase study with a relatively small number of
subjects in each treatment group. Because of potential safety
concerns, doses were escalated sequentially, rather than by
adopting the standard parallel-group design.
Despite these limitations, our study suggests that targeting
the alpha subunit of the GM-CSFR may be a novel approach to
RA treatment. Mavrilimumab, especially at the higher doses,
appears to produce rapid and clinically meaningful effects
Figure 3 Efﬁcacy according to American College of Rheumatology (ACR) assessment (ITT population). (A) ACR responses by treatment group at
week 12. (B) ACR20 responses by visit. (C) ACR50 responses by visit. (D) ACR70 responses by visit.
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across a number of disease activity parameters with no unex-
pected safety concerns. This hypothesis will be evaluated in
future larger, appropriately powered clinical studies.
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Table 2 Most frequent treatment-emergent AEs and most frequent treatment-related AEs (>1 subject in placebo or total mavrilimumab groups)
(safety population)
AE, n (%) Placebo (n=79)
Mavrilimumab
10 mg (n=39) 30 mg (n=41) 50 mg (n=40) 100 mg (n=40) Total (n=160)
Total number of AEs 74 39 40 37 29 145
Total subjects reporting ≥1 AE 36 (45.6) 25 (64.1) 24 (58.5) 19 (47.5) 23 (57.5) 91 (56.9)
Carbon monoxide diffusing capacity decreased 5 (6.3) 10 (25.6) 3 (7.3) 3 (7.5) 3 (7.5) 19 (11.9)
Nasopharyngitis 2 (2.5) 1 (2.6) 4 (9.8) 1 (2.5) 4 (10.0) 10 (6.3)
Upper respiratory tract infection 4 (5.1) 2 (5.1) 1 (2.4) 1 (2.5) 2 (5.0) 6 (3.8)
Worsening of rheumatoid arthritis 2 (2.5) 2 (5.1) 1 (2.4) 2 (5.0) 0 (0) 5 (3.1)
Transaminases increased 0 (0) 1 (2.6) 1 (2.4) 1 (2.5) 1 (2.5) 4 (2.5)
Alanine aminotransferase increased 0 (0) 0 (0) 2 (4.9) 1 (2.5) 1 (2.5) 4 (2.5)
Pharyngitis 0 (0) 0 (0) 1 (2.4) 2 (5.0) 1 (2.5) 4 (2.5)
Oral herpes 0 (0) 1 (2.6) 2 (4.9) 0 (0) 0 (0) 3 (1.9)
Hypercholesterolemia 1 (1.3) 1 (2.6) 1 (2.4) 1 (2.5) 0 (0) 3 (1.9)
Neutropenia 0 (0) 0 (0) 2 (4.9) 1 (2.5) 0 (0) 3 (1.9)
Influenza 1 (1.3) 1 (2.6) 0 (0) 2 (5.0) 0 (0) 3 (1.9)
Hepatic enzyme increased 2 (2.5) 1 (2.6) 0 (0) 0 (0) 1 (2.5) 2 (1.3)
Injection site pain 0 (0) 0 (0) 1 (2.4) 0 (0) 1 (2.5) 2 (1.3)
Anemia 4 (5.1) 1 (2.6) 0 (0) 0 (0) 1 (2.5) 2 (1.3)
Bronchitis 1 (1.3) 0 (0) 0 (0) 0 (0) 2 (5.0) 2 (1.3)
Amenorrhea 0 (0) 1 (2.6) 0 (0) 0 (0) 1 (2.5) 2 (1.3)
Skin exfoliation 0 (0) 1 (2.6) 0 (0) 1 (2.5) 0 (0) 2 (1.3)
Monocytopenia 2 (2.5) 0 (0) 0 (0) 0 (0) 1 (2.5) 1 (0.6)
Hypertension 2 (2.5) 0 (0) 1 (2.4) 0 (0) 0 (0) 1 (0.6)
Rash 2 (2.5) 0 (0) 1 (2.4) 0 (0) 0 (0) 1 (0.6)
Cough 2 (2.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Treatment-related adverse events
Total subjects reporting ≥1 related AE 11 (13.9) 8 (20.5) 9 (22.0) 8 (20.0) 7 (17.5) 32 (20.0)
Carbon monoxide diffusing capacity decreased 1 (1.3) 4 (10.3) 2 (4.9) 1 (2.5) 0 (0) 7 (4.4)
Upper respiratory tract infection 1 (1.3) 0 (0) 0 (0) 1 (2.5) 2 (5.0) 3 (1.9)
Neutropenia 0 (0) 0 (0) 2 (4.9) 1 (2.5) 0 (0) 3 (1.9)
Worsening of rheumatoid arthritis 0 (0) 0 (0) 1 (2.4) 1 (2.5) 0 (0) 2 (1.3)
Transaminases increased 0 (0) 0 (0) 0 (0) 1 (2.5) 1 (2.5) 2 (1.3)
Hepatic enzyme increased 2 (2.5) 1 (2.6) 0 (0) 1 (2.5) 0 (0) 1 (0.6)
Serious adverse events
Total subjects reporting ≥1 related SAE 1 2 2 0 0 0
AE, adverse event; SAE, serious adverse event.
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